Adaptive Biotechnologies ADPT
$27.93 −$0.12 (-0.43%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.89 -0.14%
Open$27.43
Prev close$28.05
Day range$27.15 – $28.23
Volume2.48M
Market cap$4.52B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$83.90M-10.7% YoY
Operating profit-$457,000.00-104.4% YoY
Net profit$2.81M-70.6% YoY
Diluted EPS$0.02-66.7% YoY
Free cash flow$7.68M+201.9% YoY
Operating cash flow$9.61M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin74.2%
Operating margin-16.2%
Net margin-23.7%
Return on equity-37.1%
Return on assets-12.0%
Return on invested capital-16.5%
Current ratio3.97
Liabilities / assets73.1%
Cash & investments$298.95M
Total debt$399.83M
Net cash (debt)-$100.88M
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $83.90M | $71.55M | $70.87M | $276.98M | $71.68M |
| Total Operating Revenue | $83.90M | $71.55M | $70.87M | $276.98M | $71.68M |
| Cost of Revenue | $19.93M | $20.17M | $18.71M | $71.36M | $18.22M |
| Gross Profit | $63.97M | $51.39M | $52.17M | $205.62M | $53.46M |
| Operating Expense | $64.43M | $67.16M | $71.37M | $262.74M | $66.23M |
| Selling and Admin Expenses | $45.36M | $47.58M | $47.33M | $167.27M | $44.04M |
| -Selling & Marketing Expense | $26.90M | $26.41M | $26.35M | $94.57M | $24.48M |
| -General & Admin Expense | $18.46M | $21.17M | $20.98M | $72.70M | $19.56M |
| Research & Development | $18.64M | $19.15M | $23.62M | $93.77M | $21.76M |
| Depreciation & Amortization & Depletion | $428,000.00 | $423,000.00 | $419,000.00 | $1.70M | $429,000.00 |
| -Depreciation & Amortization | $428,000.00 | $423,000.00 | $419,000.00 | $1.70M | $429,000.00 |
| Operating Profit | -$457,000.00 | -$15.77M | -$19.21M | -$57.12M | -$12.77M |
| Net Non-Operating Interest Income (Expense) | $3.26M | -$438,000.00 | -$809,000.00 | -$2.33M | -$806,000.00 |
| Non-Operating Interest Income | $3.77M | $2.26M | $2.08M | $9.44M | $2.15M |
| Non-Operating Interest Expense | $503,000.00 | $2.69M | $2.89M | $11.78M | $2.95M |
| Special Income (Charges) | $0.00 | -$23.73M | – | $0.00 | $0.00 |
| Pretax Profit | $2.81M | -$39.94M | -$20.02M | -$59.46M | -$13.58M |
| Net Profit | $2.81M | -$39.94M | -$20.02M | -$59.46M | -$13.58M |
| Profit from Continuing Operations | $2.81M | -$39.94M | -$20.02M | -$59.46M | -$13.58M |
| Minority Interests | -$70,000.00 | -$153,000.00 | $18,000.00 | $42,000.00 | $0.00 |
| Net Income to Parent Company | $2.88M | -$39.79M | -$20.03M | -$59.50M | -$13.58M |
| Net Income to Common Stockholders | $2.88M | -$39.79M | -$20.03M | -$59.50M | -$13.58M |
| Basic EPS | $0.02 | -$0.25 | -$0.13 | -$0.39 | -$0.09 |
| Diluted EPS | $0.02 | -$0.25 | -$0.13 | -$0.39 | -$0.09 |
| Other Income (Expense) | – | -$23.73M | – | – | – |
| -Less:Other Special Charges | – | $23.73M | – | – | – |
| -Less:Impairment of Capital Assets | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $683.12M | $640.68M | $505.94M | $512.74M | $512.74M |
| Total Current Assets | $392.69M | $420.56M | $291.81M | $300.19M | $300.19M |
| Cash and Cash Equivalents & Short-Term Investments | $298.95M | $344.26M | $218.33M | $226.98M | $226.98M |
| -Cash and Cash Equivalents | $75.62M | $169.87M | $77.58M | $70.50M | $70.50M |
| -Short Term Investments | $223.34M | $174.38M | $140.75M | $156.49M | $156.49M |
| Receivables | $66.67M | $49.51M | $48.32M | $50.37M | $50.37M |
| -Accounts Receivable | $66.67M | $49.51M | $48.32M | $50.37M | $50.37M |
| Inventory | $10.06M | $10.50M | $11.21M | $9.82M | $9.82M |
| Other Current Assets | $17.01M | $16.30M | $13.95M | $13.02M | $13.02M |
| Total Non-Current Assets | $290.43M | $220.12M | $214.14M | $212.55M | $212.55M |
| Net PPE | $65.96M | $68.57M | $71.02M | $74.72M | $74.72M |
| -Gross PPE | $65.96M | $68.57M | $71.02M | $170.51M | $170.51M |
| Investments and Advances | $101.23M | $27.48M | $18.89M | $13.23M | $13.23M |
| -Available for Sale Securities | $101.23M | $27.48M | $18.89M | $13.23M | $13.23M |
| Goodwill and Other Intangible Assets | $119.43M | $119.86M | $120.28M | $120.70M | $120.70M |
| -Goodwill | $118.97M | $118.97M | $118.97M | $118.97M | $118.97M |
| -Other Intangible Assets | $456,000.00 | $884,000.00 | $1.31M | $1.73M | $1.73M |
| Other Non-Current Assets | $3.82M | $4.21M | $3.95M | $3.90M | $3.90M |
| Total Liabilities | $499.23M | $490.02M | $281.70M | $287.74M | $287.74M |
| Total Current Liabilities | $98.97M | $87.71M | $87.01M | $89.92M | $89.92M |
| Payables | $6.53M | $5.24M | $9.62M | $7.01M | $7.01M |
| -Accounts Payable | $6.53M | $5.24M | $9.62M | $6.47M | $6.47M |
| Current Accrued Expenses | $8.20M | $10.65M | $7.47M | $7.16M | $7.16M |
| Short-Term Debt and Capital Lease Obligation | $9.14M | $8.82M | $8.51M | $8.92M | $8.92M |
| -Current Capital Lease Obligation | $9.14M | $8.82M | $8.51M | $8.92M | $8.92M |
| Current Deferred Liabilities | $60.00M | $53.26M | $49.40M | $45.19M | $45.19M |
| Total Non-Current Liabilities | $400.26M | $402.30M | $194.69M | $197.82M | $197.82M |
| Long Term Debt and Capital Lease Obligation | $399.83M | $401.68M | $69.12M | $70.23M | $70.23M |
| -Long Term Debt | $335.38M | $334.88M | – | – | – |
| -Long Term Capital Lease Obligation | $64.46M | $66.80M | $69.12M | $70.23M | $70.23M |
| Non-Current Deferred Liabilities | $408,000.00 | $608,000.00 | $807,000.00 | $1.01M | $1.01M |
| Other Non-Current Liabilities | $20,000.00 | $20,000.00 | $124.77M | $126.59M | $126.59M |
| Total Equity | $183.89M | $150.66M | $224.24M | $225.00M | $225.00M |
| Stockholders' Equity | $176.21M | $142.91M | $216.34M | $218.79M | $218.79M |
| Capital Stock | $16,000.00 | $16,000.00 | $16,000.00 | $15,000.00 | $15,000.00 |
| -Common Stock | $16,000.00 | $16,000.00 | $16,000.00 | $15,000.00 | $15,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.60B | $1.57B | $1.60B | $1.58B | $1.58B |
| Retained Earnings | -$1.42B | -$1.42B | -$1.38B | -$1.36B | -$1.36B |
| Gains/Losses Not Affecting Retained Earnings | -$1.29M | -$212,000.00 | -$28,000.00 | $253,000.00 | $253,000.00 |
| Minority Interests | $7.68M | $7.75M | $7.90M | $6.21M | $6.21M |
| Other Current Liabilities | – | – | $5.80M | $4.64M | $4.64M |
| -Accumulated Depreciation | – | – | – | -$95.79M | -$95.79M |
| -Total Tax Payable | – | – | – | $541,000.00 | $541,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $9.61M | -$6.40M | -$9.54M | -$45.99M | $2.06M |
| Net cash flow from continuing operations | $9.61M | -$6.40M | -$9.54M | -$45.99M | $2.06M |
| Net Income from Continuing Operations | $2.81M | -$39.94M | -$20.02M | -$59.46M | -$13.58M |
| Depreciation & Depletion & Amortization | $3.61M | $3.70M | $3.84M | $17.83M | $4.20M |
| Other Non-Cash Items | $1.54M | $18.61M | $807,000.00 | $3.87M | $843,000.00 |
| Change in Working Capital | -$8.02M | $222,000.00 | -$6.30M | -$57.77M | -$2.45M |
| -Change in Receivables | -$17.16M | -$1.20M | $2.05M | -$8.65M | -$5.54M |
| -Change in Inventory | $489,000.00 | $561,000.00 | -$1.32M | -$998,000.00 | -$10,000.00 |
| -Change in Prepaid Assets | -$1.45M | -$1.70M | -$824,000.00 | -$1.73M | $799,000.00 |
| -Change in Payables and Accrued Expense | $5.22M | $1.01M | -$7.51M | $665,000.00 | $1.17M |
| -Change In Other Working Capital | $4.88M | $1.55M | $1.31M | -$47.06M | $1.14M |
| Net cash flow from investing | -$125.06M | -$43.48M | $9.14M | $37.95M | -$8.25M |
| Net Cash Flow from Continuing Investing Activities | -$125.06M | -$43.48M | $9.14M | $37.95M | -$8.25M |
| Net PPE Purchase and Sale | -$1.93M | -$1.18M | -$796,000.00 | -$2.96M | -$636,000.00 |
| Net Investment Purchase and Sale | -$123.13M | -$42.29M | $9.94M | $40.91M | -$7.62M |
| Financing Cash Flow | $21.17M | $142.19M | $7.50M | $30.40M | $21.66M |
| Net Cash Flow from Continuing Financing Activities | $21.17M | $142.19M | $7.50M | $30.40M | $21.66M |
| Net Issuance Payments Of Debt | -$680,000.00 | – | – | – | – |
| Net Common Stock Issuance | $0.00 | – | – | – | – |
| Proceeds from Stock Option Exercised | $21.85M | $5.38M | $5.03M | $17.88M | $9.13M |
| Net Other Financing Charges | $0.00 | -$173.71M | $2.48M | $12.52M | – |
| Ending Cash Balance | $78.32M | $172.60M | $80.29M | $73.18M | $73.18M |
| Net Change in Cash | -$94.28M | $92.31M | $7.11M | $22.37M | $15.46M |
| Beginning Cash Balance | $172.60M | $80.29M | $73.18M | $50.82M | $57.72M |
| Free Cash Flow | $7.68M | -$7.58M | -$10.33M | -$48.95M | $1.42M |
No comments yet — be the first to weigh in on ADPT.
Sign in to join the discussion.